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Available online 6 October 2016To put a Respiratory Syncytial Virus (RSV) vaccine onto themarket, new vaccination strategies combining scien-
tiﬁc and technical innovations need to be explored. Such a vaccine would also need to be adapted to the vaccina-
tion of young children that are the principal victims of acute RSV infection. In the present project, we describe the
development and the preclinical evaluation of an original epicutaneous RSV vaccine that combines two technol-
ogies: Viaskin® epicutaneous patches as a delivery platform and RSV N-nanorings (N) as a subunit antigen. Such
a needle-free vaccine may have a better acceptability for the vaccination of sensible population such as infants
since it does not require any skin preparation. Moreover, this self-applicative vaccine would overcome some is-
sues associated to injectable vaccines such as the requirement of sterile medical devices, the need of skilled
health-care professionals and the necessity of stringent store conditions. Here, we demonstrate that Viaskin®
patches loaded with a formulation containing N-nanorings (Viaskin®-N) are highly immunogenic in mice and
promotes a Th1/Th17 oriented immune response. More importantly, Viaskin®-N epicutaneous vaccine confers
a high level of protection against viral replication upon RSV challenge in mice, without exacerbating clinical
symptoms. In swine, which provides the best experimental model for the transcutaneous passage of drug/anti-
gen in human skin, we have shown that GFP ﬂuorescent N-nanorings, delivered epicutaneously with Viaskin®
patches, are taken up by epidermal Langerhans cells. We have also demonstrated that Viaskin®-N induced a sig-
niﬁcant RSV N-speciﬁc T-cell response in pig. In conclusion, Viaskin®-N epicutaneous vaccine seems efﬁcient to
protect against RSV infection in animal model.






The development of a safe and effective RSV vaccine for infants in the
ﬁrst six months of life is a public health challenge for reducing the se-
vere burden of RSV-associated respiratory diseases, especially bronchi-
olitis and hospitalizations. Globally, it is estimated that RSV causes
N30 million lower respiratory tract infections each year resulting in N3
million hospitalizations, making it the most common cause of hospital-
izations in children under 5 [1]. Moreover, severe RSV incidence is
highest in infants younger than 5 months.s.com (P.-L. Hervé),
abine.riffault@jouy.inra.fr
l, 91000 Evry, France.
. This is an open access article underDevelopment of RSV vaccines has been complicated by the dramatic
outcomeof theﬁrst clinical trial in the 60′s, which examined the efﬁcacy
of a formalin-inactivated virus vaccine (FI-RSV) in infants and young
children. Indeed, this vaccine formulation exacerbated clinical symp-
toms upon RSV infection and led to the hospitalization of almost 80%
of the vaccinated children [2].
To date, there is no available vaccine against RSV. A large array of al-
ternative vaccination strategies (antigen candidates and routes of ad-
ministration) are being explored, but without providing satisfactory
solutions [3–5]. There are indeed major challenges unique to RSV relat-
ed to i) the young age of infection, ii) the failure of natural infection to
induce immunity that prevents re-infection, and iii) the risk of im-
mune-mediated disease exacerbation. Furthermore, due to the young
age of the target population, a non-invasive and painless vaccine ap-
proach would be highly desirable.
In the present study, we evaluated a novel vaccination strategy
against RSV that combines two original technologies: Viaskin®the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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[6] and RSV nucleoprotein nanorings (N-nanorings) as a subunit anti-
gen (patents WO/2007/119011 and WO/2006/117456) [7,8]. Puriﬁed
recombinant RSV N assembles as soluble nanorings of 15 nm diameter,
composed of 10 to 11 N protomers bound to a bacterial RNA of 70 bases
[9,10]. These N-nanorings, when administered intranasally, induce po-
tent local and systemic immune responses inmice and calves and confer
protection against an RSV challenge [11,12]. Protection afforded by
N-nanorings in mice correlates with the presence of potent N-speciﬁc
CD4 and CD8 T-cell responses [11]. N-nanorings are also able to induce
a strong anti-N humoral response. However, these antibodies are
non-neutralizing and passive transfer experiments performed in
mice suggested that they possess no effective role in protection [11].
Skin has been recently explored as an original route for immuniza-
tion, especially for the induction of a potent mucosal immune response
against respiratory, gastro-intestinal or sexually transmissible patho-
gens [13]. Several vaccine strategies have been explored for the transcu-
taneous delivery of antigens [14]. However, due to the difﬁculty to get
through the skin's top dead layer (stratum corneum), the vast majority
of these approaches requires a preparation of the skin such as mechan-
ical or chemical disruption, or the use of microneedles [15]. A few years
ago, a novel epicutaneous delivery system was designed by DBV Tech-
nologies for food allergy desensitization [16]. This system is composed
of patches (Viaskin® technology) that form an occlusive condensation
chamber where allergen is solubilized by skin perspiration (skin hydra-
tion) and delivered across the stratum corneum to the epidermis with-
out any skin preparation (see Graphical abstract) [16–22]. More
recently, DBV Technologies got the proof-of-concept that Viaskin®
patches can also be used as an efﬁcient vaccine delivery platform in a
murinemodel, in the context of Bordetella pertussis (B. pertussis) booster
vaccine development [23]. Indeed, a single application of Viaskin®
patch loadedwith genetically-detoxiﬁed pertussis toxin (rPT), in the ab-
sence of adjuvant, was able to efﬁciently recall memory vaccine-in-
duced immunity against B. pertussis.
The skin barrier is composed of a dense network of antigen present-
ing cells (APCs), including dendritic cells (DC) such as Langerhans cells
(LC) that resides in the epidermis layer [24]. These DC provide immune-
surveillance by “sensing” pathogens passing through stratum corneum
and play a central role to activate the adaptive immunity. Our group
has pioneered the characterization of DC subsets within the skin of pig
and shown that it shares many similarities with human skin DC [25].
In fact, pig skin histology is very similar to the human one's and is
thus recognized as one of themost appropriate model to study delivery
of pharmaceutical compounds via skin [25–27]. Thus we investigated in
piglets whether ﬂuorescent N-nanorings fused to GFP would reach skin
immune cells when administered with the Viaskin® platform. We ob-
served both an internalization of N-GFP antigen by skin Langerhans
cells and the induction of antigen-speciﬁc cellular immune responses
in spleen.
The immunization procedure with N-nanorings-loaded Viaskin®
patches (Viaskin®-N) was further investigated in mice in order to char-
acterize the antiviral immune response elicited and its capacity to pro-
tect against challenge with an RSV-Luciferase recombinant virus.
Viaskin®-N vaccination elicited a strong antigen-speciﬁc cellular re-
sponse in mice and piglets. In mice, Viaskin®-N promotes a Th17/Th1
oriented immune response and conferred protection against virus repli-
cation in lungs.
2. Material and methods
2.1. Plasmid construction, protein expression and puriﬁcation of
N-nanorings
Expression and puriﬁcation of recombinant nucleoprotein (N) was
performed as previously described [9]. Brieﬂy, the puriﬁcation of
the recombinant N protein is permitted by its speciﬁc interactionwith the C-terminal region of RSV P protein (PCT) (residues 161–241)
fused to GST. E. coli BL21 (DE3) bacteria were co-transformed with
pGEX-PCT and pET-N and then grown at 37 °C for 8 h in 1 L of Luria-
Bertani (LB) medium containing 100 μg/mL of ampicillin and 50 μg/
mL of kanamycin. The same volume of LB medium was then added,
and protein expression was induced by adding 80 μg/mL isopropyl-β-
D-thiogalactopyranoside (IPTG) to the medium. Bacteria were incubat-
ed for a further 15 h at 28 °C and harvested by centrifugation. Protein
complexes were puriﬁed from the bacterial pellets on glutathione-se-
pharose 4B beads (GE Healthcare, Uppsala, Sweden) as previously de-
scribed [28]. To isolate N-nanorings, beads containing bound
complexes were incubated with biotinylated thrombin (Merck
Millipore, Darmstadt, Germany) for 16 h at 20 °C. Thrombin was then
removed using the cleavage capture kit according to themanufacturer's
instructions (Merck Millipore, Darmstadt, Germany). Puriﬁed N-nano-
rings were then concentrated on Vivaspin® centrifugal concentrator
(Sartorius, Goettingen, Germany) and sterilely ﬁltered. Of note, a
small amount of PCT was co-puriﬁed with chimeric N-nanorings. How-
ever, we previously demonstrated that PCT is poorly immunogenic and
induced a low anti-P antibody response by comparisonwith the entire P
protein [29]. N-nanorings fused to Green Fluorescent Protein (N-GFP)
was constructed as previously described [11]. Brieﬂy, the EGFP coding
sequence was cloned onto pET-N plasmid. The resulting plasmid was
designated as pET-N-GFP and encode for a chimeric N protein fused to
EGFP at its C-terminus. The expression and the puriﬁcation protocols
of N-GFP were identical to those of N protein alone.
2.2. Production of N-nanorings-loaded Viaskin® patches (Viaskin®-N)
N- and N-GFP- nanorings were puriﬁed as described above. Then, a
homogeneous mix between N- or N-GFP nanorings and CpG was
made in PBS to a respective concentration of 1 mg/mL. 50 μL (mice im-
munization) or 100 μL (piglets immunization) were then homoge-
neously deposited on Viaskin® patches and dried 1 h at 30 °C in a
ventilated oven to produce Viaskin®-N and Viaskin®-N-GFP, respec-
tively. The stability of N-nanorings after their deposition on Viaskin®
patches was then controlled by native gel electrophoresis, electronic
microscopy and DLS after recovery from the matrix of the patch (Fig.
S1). Results showed that N-nanorings integrity was preserved upon de-
position and drying on Viaskin® patches.
2.3. Mice: immunization, challenge protocols and sample collection
Female BALB/c mice aged 6 weeks were purchased from Janvier's
breeding center (Le Genest, St Isle, France) and housed under Bio-Safety
Level (BSL)-2 conditions in the animal facility (IERP, INRA, Jouy-en-
Josas, France). All experiments were carried out in INRA (Rodent Exper-
imental Infectiology Platform, Jouy-en-Josas, France) and approved by
the ethics committee COMETHEA (Ethical Committee for Animal Exper-
imentation, INRA and AgroParisTech; authorization number 12-126).
All efforts were made to optimize animal welfare (environmental en-
richment) and avoid suffering.
For Viaskin® patches immunization, mice were anesthetized with a
solution of ketamine and xylazine (50 and 10 mg/kg respectively) and
hairs were removed from the back of each mouse using an electric clip-
per and then a depilatory cream (Veet®, Reckitt Benckiser, Slough,
Berkshire, United Kingdoms). N-rings loaded Viaskin® (Viaskin®-N)
was applied on the depilated back the day after and secure using a
bandage (Urgoderm®band-aid, Urgo laboratories, Chenôve, France).
For intra-nasal immunizations, mice were anesthetized with a solu-
tion of ketamine and xylazine (50 and 10 mg/kg respectively) and vac-
cinated twice at 2 weeks interval by intra-nasal instillation of 50 μL of
0.9% endotoxin-free NaCl, containing 10 μg of N-nanorings, associated
to 10 μg of CpG ODN (1826) (T*C*C*A*T*G*A*C*G*T*T*C*C*
T*G*A*C*G*T*T, Sigma-Aldrich, Saint Louis, Missouri).
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lution of ketamine and xylazine (50 and 10 mg/kg respectively) and
vaccinated twice at 2 weeks interval by intra-dermal injection of 50 μL
of 0.9% endotoxin-free NaCl, containing 10 μg of N-nanorings, associated
to 10 μg of CpG ODN (1826).
Twoweeks after the last Viaskin®or intra-nasal immunization,mice
were anesthetized and inoculated intra-nasally with 8.8 × 104 PFU of
RSV-Luciferase virus [30]. This recombinant virus was generated from
RSV Long strain and expresses ﬁreﬂy luciferase in infected cells,
allowing us to detect viral replication in living mice via the lumines-
cence emitted after the transformation of D-luciferin substrate into
oxyluciferin. Of note, this virus presents the same virulence as RSV
Long WT and luminescence values measured from infected animals
fully correlate with viral replication as previously described [30]. After
infection, body weight and clinical score were monitored daily.
Blood samples were collected via cheek puncture at day 0 (before
immunization), day 14 and 35. At autopsy, mice were killed by cervical
dislocation. Broncho-alveolar lavages (BAL)were performedby ﬂushing
the lungs via tracheal puncture two times in and out with 1mL of Ca2+-
and Mg2+-free PBS supplemented with 1 mM EDTA. BAL ﬂuids were
centrifuged 5 min at 250 ×g and supernatants were stored frozen at
−20 °C for anti-N antibody titers measurement.
2.4. Piglets: Viaskin® immunization protocol and sample collection
Piglets were purchased and housed in our animal facility (INRA,
IERP, Nouzilly, France). All experiments were carried out in INRA (Ex-
perimental Infectiology Platform, Nouzilly, France) and approved by
the ethics committee CEEA VdL (Ethical Committee for Animal Experi-
mentation, Val de Loire; authorization number CEEA VdL N°19). All ef-
forts were made to optimize animal welfare (environmental
enrichment) and avoid suffering.
For the study of the passage of N-GFP through the skin, 4 weeks old
piglets were shaved and depilated on their ﬂanks using an electric
depilator. N-GFP loaded Viaskin® (Viaskin®-N-GFP) was applied on
the depilated ﬂank the day after and secure using Tegaderm® bandage
(3M, Saint Paul, Minnesota) and Elastoplast® band-aid (Beiersdorf,
Hamburg, Germany). Viaskin®-N-GFP was applied for 24 h or 48 h
and piglets were autopsied 24 h after Viaskin® removal or just after
Viaskin® removal. At autopsy, piglets were slightly anesthetized, then
euthanized with an intra-cardiac injection of Dolethal® (Vetoquinol,
Magny-Vernois, France). Skin samples were then collected from the
area corresponding to patches location. Skin sample was immediately
frozen in Tissue-Tek® O.C.T. embedding solution (Sakura Finetek,
Tokyo, Japan) for subsequent histological analysis.
For immunogenicity study, 8 weeks old piglets were shaved and
depilated on their ﬂanks using an electric depilator. After 24 h,
Viaskin® patches loaded with N-nanorings and swine CpG ODN
(G*GTGCATCGATTTATCGATTATCGATGCAGG*G*G*G*G, Sigma-Aldrich,
Saint Louis, Missouri) was applied on their left ﬂank and secured as de-
scribed above. Viaskin®-N application was repeated 6 times during 3
contiguous weeks, modelling the immunization protocol that have
been implemented in mice. Alternatively, piglets were immunized by
intra-muscular injection, twice at two weeks interval, with 20 μg of
N-nanorings, adjuvanted with Montanide™ ISA 71 VG. Blood and nasal
swab samples were collected before and every week after the ﬁrst immu-
nization, during 5 weeks. Piglets were autopsied 2 weeks after the last
Viaskin®-N application. Piglets were euthanized as described above and
spleen were collected for in vitro stimulation of T-cells.
2.5. Evaluation of anti-N antibody responses by ELISA
Individual mouse sera and BAL were assayed for anti-N antibodies
(Ig(H + L), IgG2a, IgG1 or IgA) by indirect ELISA using N nanorings as
the capture antigen (200 ng per well on microplates), as previously de-
scribed [11]. Individual piglet sera were assayed similarly for anti-Nantibodies using HRP-conjugated anti swine Ig(H + L) secondary anti-
body (Jackson ImmunoResearch, West Grove, Pennsylvania). End-
point antibody titers were calculated by regression analysis, plotting
serum dilution versus the absorbance at 450 nm using Microcal Origin
(OriginLab Corporation, Northampton, Massachusetts) (regression
curve y = ((b + cx) / (1 + ax)). Endpoint titers were deﬁned as the
highest dilution resulting in an absorbance value twice that of blank
points (points realized with diluent buffer).
2.6. Evaluation of N-speciﬁc T-cell response in mice and piglets
For mice experiment, spleen were collected two weeks after the last
immunization and gently homogenized in RPMI medium using a
100 μm nylon cell-strainer (Falcon). Red blood cells were depleted
using 150 mM NH4Cl and splenocytes were adjusted to 2.106 viable
cells/mL in RPMI supplemented with 10% of foetal calf serum (FCS)
and 2 mM L-glutamine. Then, 4.105 cells/well were distributed in 96-
well ﬂat-bottomedmicrotiter plates. Cells were then incubated in tripli-
cates with either N-nanorings (10 μg/mL ﬁnal concentration in RPMI
medium) or RPMI medium alone as a negative control. Cell cultures
were incubated at 37 °C in 5% CO2, and supernatants were harvested
72 h later. Supernatants were assayed for IFN-γ and IL-5 by standard-
ized ELISA (BD biosciences, Franklin Lakes, New Jersey) as previously
described [31] or by multiplex analysis as described below.
For piglet experiment, spleenwere collected twoweeks after the last
immunization and gently homogenized in PBS-Citrate 1.3 mMmedium
using a 100 μm nylon cell-strainer (Falcon). Red blood cells and cell de-
bris were then eliminated by ﬁcoll density gradient centrifugation,
30min at 1000×g. Spleen cellswere stainedwith 2 μMCarboxyFluores-
cein Succinimidyl Ester (CFSE, ThermoFisher, Waltham,Massachusetts)
10 min at room temperature (RT). Then, 6.105 cells per well were de-
posited on microplates and mix with N-nanorings (10 μg/mL ﬁnal con-
centration in Xvivo medium) or Xvivo medium alone as a negative
control. Cell cultures were incubated at 37 °C in 5% CO2 for 72 h and su-
pernatants were harvested for measuring IFN-γ by ELISA. Fresh Xvivo
mediumwas then added on each well and cells were incubated for an-
other 48 h. Finally, cells were collected for immuno-staining and FACS
analysis.
2.7. Measure of swine IFN-γ secretion by sandwich ELISA
Spleen cells collected from immunized piglets were stimulated in
vitro as described above. Cell culture supernatants were collected at
72 h post-stimulation and were assayed for IFN-γ concentration by
sandwich ELISA. To that end, microplates were coated with 200 ng of
mAb-pIFN-γ (Mabtech, Cincinnati, Ohio) overnight at 4 °C. Plates
were saturatedwith PBS 1× tween 20 0.05%+ 0.1% bovine serum albu-
min (BSA) 1 h at RT and 100 μL of cell culture supernatants were added
for 2 h at RT. Bounded IFN-γ was detected by subsequent incubations
withmAb PAN-biotin (Mabtech, Cincinnati, Ohio) (0.5mg/mLﬁnal con-
centration) for 1 h at RT andHRP-conjugated streptavidin (1 μg/mLﬁnal
concentration) for 1 h at RT. HRP enzymatic activitywasﬁnally revealed
using a 1-step Ultra TMB substrate (Thermo Scientiﬁc,Waltham,Massa-
chusetts) and optical density was read at 450 nm wavelength using an
Inﬁnite® 200 pro Microplates reader (Tecan, Männedorf, Switzerland).
2.8. Antibodies and FACS staining
For skin passage study in piglets, skin cells were labelled and ana-
lyzed as previously described [25]. Brieﬂy, skin samples were incubated
overnight at 37 °C in RMPI complemented with 10% FCS containing
0.5 mg/mL of DNase I and 1 mg/mL of collagenase, and ﬁltered on
100 μm nylon cell-strainer (Falcon). Cells were then collected and
enriched in low-density cells such as dendritic cells and macrophages
by OptiPrep density gradient (Sigma-Aldrich, Saint Louis, Missouri) as
previously described [32]. Cells were then blocked in PBS containing
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SIRPα 74-22-15, anti-MHC-II Th21A (from Monoclonal Antibody Cen-
ter, Washington State University, Pullmann, WA), anti-CD163 3A10
(ABD Serotec, Oxford, United-Kingdoms), anti-CD11c (in house clone
3A8) antibodies containing 5% horse serum for 1 h. These markers per-
mit to discriminate between the different skin DC sub-populations. Cells
were washed in PBS complemented with 2 mM EDTA and ﬁnally incu-
bated with relevant ﬂuorophore-conjugated isotype-speciﬁc secondary
antibodies (Thermo Scientiﬁc, Waltham, Massachusetts). GFP signal
was measured from these different sub-populations by FACS analysis.
Cells were acquired and analyzed using an LSRFortessa cytometer and
the Diva software (Becton Dickinson, Franklin Lakes, New Jersey) and
results were analyzed using the FloJow software (FloJow, LLC, Ashland,
Oregon).
For piglet immunization study, spleen cells collected from immu-
nized piglets were stained with CFSE and stimulated in vitro as
described above. Stimulated cells were collected at 5 days post-
stimulation. Cells were then stained with 7-Aminoactinomycine D
(7-AAD) to exclude dead cells and with anti-CD3 (8E6), anti-CD4
(74-12-14) and anti-CD8 (76-2-11) antibodies associated to relevant
ﬂuorophore-conjugated secondary antibodies following the protocol
described above. Cells were acquired and analyzed as mentioned
above. The gating strategy is described in Supplementary Fig. 2 (Fig. S2).
For mice immunization study, spleen cells collected from immu-
nized mice were stained with CFSE and stimulated in vitro as described
above. Stimulated cells were collected at 5 days post-stimulation. Cells
were then stained with anti-CD3, anti-CD4 and anti-CD8 antibodies
conjugated to relevant ﬂuorophores (Sony Biotechnology, Tokyo,
Japan) in PBS containing 2% SVF. Cells were additionally stained with
Zombie Aqua to exclude dead cells. Cells were then ﬁxed and perme-
abilized using the Foxp3/Transcription Factor Fixation/Permeabilization
buffer (eBioscience, San Diego, California) and stained with anti-FoxP3,
anti-T-bet, anti-GATA-3 and anti-RORγt conjugated to relevant
ﬂuorophores (Sony Biotechnology, Tokyo, Japan). Cells were acquired
and analyzed as mentioned above. The gating strategy is described in
Supplementary Fig. 3 (Fig. S3).
2.9. Immuno-histological staining of skin samples
Piglet skin were snap frozen in OCT (Sakura, Paris, France) and cryo-
sections were mounted on glass slides (Superfrost plus, Thermo Scien-
tiﬁc). Cryosections were air-dried and ﬁxed and permeabilized using
cold acetone/methanol bath and then blocked in PBS containing 5% of
horse serum and 5% of swine serum. Slides were incubated with rabbit
anti-N Ig, mouse anti-MHC-II IgG2a andmouse anti-CD163 IgG1 prima-
ry antibodies. Sliceswere then extensivelywashed in PBS and incubated
with AF488 anti-rabbit IgG, AF55 anti-mouse IgG2a and AF647 anti-
mouse IgG1 secondary antibodies. Finally, slices were stained with
DAPI. Slides were observed using a ﬂuorescent microscope coupled to
a high resolution Pannoramic digital slide scanner and images were an-
alyzed using Case Viewer software (3DHISTECH, Budapest, Hungary).
2.10. Production of recombinant RSV-luciferase fused for viral challenge
For viral challenges, we used a recombinant RSV containing the ﬁre-
ﬂy luciferase gene (RSV-luciferase). This recombinant virus allows the
visualization of infected cells in livingmice, via the emission of lumines-
cence [30]. For the production of viral stocks used for challenge, RSV-lu-
ciferase was ampliﬁed on HEp-2 cells at a low multiplicity of infection
(10−3) to eliminate potential defective interfering particles. Infected
cells were gently shaken each day to detach syncytia and spread the in-
fection to the whole cell monolayer. After 3 days, supernatant and in-
fected cells were both collected using a Cell Scraper. Cell suspension
was then sonicated 2 × 1 min to dissociate viral particles from cells
and clariﬁed by centrifugation 5 min at 400 ×g. Supernatant wasaliquoted and ﬂash-frozen using a mix of ethanol absolute and dry ice.
Aliquots were then immediately stored at−80 °C.
2.11. Determination of RSV viral load in living mice
Viral loads were measured in living mice via photon emission that
was representative of RSV-Luciferase replication, as previously de-
scribed [30]. Brieﬂy,micewere anesthetizedwith a solution of ketamine
and xylazine (50 and 10 mg/kg respectively) and 0.75 mg/kg of
D-luciferine (Sigma-Aldrich, Saint Louis, Missouri) diluted in sterile
PBS was instilled intranasally. Viral replication was estimated 5 min
later using an In Vivo Imaging System (IVIS-200) and Live Imaging soft-
ware (Xenogen Advanced Molecular Vision, Grantham, United
Kingdom's), bymeasuring the photon emission fromRegions of Interest
(ROI). Alternatively, lungs were homogenized in 500 μL of Passive Lysis
Buffer (PLB) (1mM Tris pH 7.9; 1 mMMgCl2; 1% Triton ×100; 2% glyc-
erol; 1 mMDTT) with a Precellys 24 bead grinder homogenizer (Bertin
Technologies, St Quentin en Yvelines, France) 2 × 15 s at 4m/s. Lung ho-
mogenates were clariﬁed by centrifugation 5 min at 2000 ×g and dis-
tributed on microplates. Then, 1 μg/mL (ﬁnal concentration) of ﬁreﬂy
luciferine in PLB complemented with 0.5 mM of ATP was added on
each well and photon emission was measured using the IVIS system
(Xenogen, Advanced Molecular Vision). ROIs were deﬁned in order to
ﬁt to lungs in living mice or to each wells in microplates. Photon emis-
sionmeasured fromROIswas expressed in photons per second. The col-
orimetric scale used in mice photograph is expressed in radiance
(photons/sec/cm2/sr), which is the number of photons (p) per second
(sec) that leave a square centimeter (cm2) of tissue and radiate into a
solid angle of one steradian (sr).
2.12. May-Grünwald-Giemsa staining and histology in mice
BAL cells isolated from individual mice were numerated, spread on
microscope Superfrost™ slides (Thermo Scientiﬁc, Waltham, Massa-
chusetts) by cytocentrifugation (5 min at 700× rpm) using Shandon
Cytospin® 5 (Thermo Scientiﬁc, Waltham, Massachusetts) and stained
with May-Grünwald and Giemsa. At least 400 leukocytes were counted
blindly for each sample.
Lungs collected at day 11 post-infection were ﬁxed with PBS con-
taining 10% paraformaldehyde (PBS-PFA), embedded in parafﬁn and
5 mm sections and ﬁnally mounted on glass slides (Superfrost plus,
Thermo Scientiﬁc). Slides were stained by Hematoxylin Eosin Safran
(HEC) or alcian blue. Slides were observed using a bright-ﬁeld micro-
scope coupled to a high resolution Pannoramic digital slide scanner
and images were analyzed using Case Viewer software (3DHISTECH,
Budapest, Hungary). Images were analyzed and interpreted by an inde-
pendent professional histopathologist.
2.13. Measure of cytokine concentration by multiplex analysis
Cytokine levels were measured from mouse BAL or lung homoge-
nates using a mouse cytokine & chemokine panel 1 Affymetrix
ProcartaPlex®Multiplex immunoassay (eBioscience, San Diego, Califor-
nia), following manufacturer instructions. Cytokine levels were mea-
sured from spleen culture supernatants using a Bio-Plex Pro™ Mouse
Cytokine Immunoassay (Bio-Rad, Hercules, California), followingmanu-
facturer instructions. Data were acquired using a Bio-Plex® multiplex
system (Bio-Rad, Hercules, California). Results were analyzed using
ProcartaPlexAnalyst software (eBioscience, San Diego, California) or
using the Bio-Plex® software (Bio-Rad, Hercules, California).
2.14. Statistical data analysis
Data were expressed as arithmetic mean ± Standard Error of the
Mean (SEM). Non-parametricMann-Whitney test was used to compare
unpaired values (GraphPad Prism® software, San Diego, California).
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niﬁcance is indicated on the graphs with asterisks: * P b 0.05;
** P b 0.01; *** P b 0.001 and **** P b 0.0001.
3. Results
3.1. N-rings administered via Viaskin® patches target Langerhans cells (LC)
in piglet skin
We ﬁrst evaluated the capacity of N antigen to reach and target cu-
taneous dendritic cells (DC) when administered with Viaskin® patches
in piglets. For that purpose, we used N-nanorings fused to GFP (N-GFP)
whose ﬂuorescence can be tracked in vivo and ex vivo (Fig. 1). Piglets re-
ceived Viaskin®-N-GFP for 48 h andwere sacriﬁced 24 h after patch re-
moval (group 1) or received Viaskin®-N-GFP for 24 h and were
sacriﬁced just after patch removal (group 2). For each piglet, a skin biop-
sy corresponding to Viaskin®-N-GFP application area was collected
from both ﬂanks (Fig. 1A). Fluorescence microscopy results, obtained
from skin cryosections, showed a close co-localization between the
GFP signal and the stratum corneum for group 2 (left ﬂank). Conversely,
no GFP signal was detected at the skin surface for group 1, suggesting
that N-GFP protein was washed away from the stratum corneum over
the 24 h interval between patch removal and autopsy (Fig. 1B). FewFig. 1.N-nanorings delivered via Viaskin® patches are captured by Langerhans cells in piglet sk
fused to Green Fluorescent Protein (GFP) and 100 μg of CpG on their left ﬂank (Viaskin®-N-GFP
CpG alone on their right ﬂank (Viaskin® excipient). This skin area has been selected from persp
(perspiration). Perspiration values were also indicative of a good skin integrity (data not sho
removal. Group 2 received Viaskin®-N-GFP for 24 h and was autopsied just after Viaskin® re
frozen sections were prepared, then ﬁxed, permeabilized and incubated with rabbit anti-N Ig
relevant ﬂuorophore-conjugated secondary antibodies. (B) A representative photograph of on
of the group 2, showing GFP signal in Langerhans cells (SC: stratum corneum, E: epidermis, D
dispase/collagenase digestion. Skin cells were then incubated with anti-CD163, anti-CD172 (SI
secondary antibodies. Cells were analyzed using an LSR Fortessa ﬂow cytometer. Gating o
mean + SEM of individual values (n = 4 per experimental group), expressed as the indiv
determined according to the Mann-Whitney test (*, P b 0.05).rare GFP signals could be detected in skin sections of the group 2 (Fig.
1C), co-localizing with MHC-IIhigh cells. We then chose ﬂow cytometry,
amuchmore sensitivemethod for faint and rare events, and used a pre-
viously described gating strategy allowing us to discriminate the differ-
ent DC and macrophages populations of the swine skin [25]. We were
able to detect a signiﬁcant increase of GFP signal in Langerhans cells
(LC) of the group 1 (P b 0.05), but not in other DC subtypes (cDC-1
and cDC-2) (Fig. 1D). Overall, these data indicate that N-nanorings de-
livered epicutaneously by Viaskin® patches are efﬁciently captured by
epidermal LC. This encouraging result prompted us to analyze the na-
ture of the immune response that could be induced by Viaskin®-N im-
munization in mice and piglet, as well as the protection afforded in an
experimental mouse model of RSV infection.
3.2. Implementation of an epicutaneous vaccination protocol with
Viaskin®-N in mice
The Viaskin®-N formulation and immunization schedule were opti-
mized in BALB/cmice.We used CpGODNas an adjuvant to promote Th1
responses known to be important for safe and protective RSV vaccina-
tion, especially in the context of neonates [33].
Mice immunized with Viaskin®-N and CpG ODN developed signiﬁ-
cant titers of anti-N antibodies after three patch applications, both ofin. (A) 2 groups of piglets received 6 Viaskin® patches loaded with 100 μg of N-nanorings
). As a negative control, the same piglets received 6 Viaskin® patches loadedwith 100 μg of
iration measurement data, showing that the ﬂank generated a sufﬁcient level of humidity
wn). Group 1 received Viaskin®-N-GFP for 48 h and was autopsied 24 h after Viaskin®
moval. At autopsy, skin samples were collected and frozen in embedding solution. Skin
, mouse anti-MHC-II IgG2a and mouse anti-CD163 IgG1 primary antibodies associated to
e section of each group is shown. (C) Photograph of a skin section collected from a piglet
: dermis). (D) Cells were isolated from skin samples of the groups 1 and 2, by overnight
RP) and anti-MHC-II (MSA3) antibodies associated with relevant ﬂuorophore-conjugated
f cDC-1, cDC-2 and Langerhans cells was done as previously described [25]. Data are
idual % of GFP positive cells among each of the skin DC subpopulations. P values were
151P.-L. Hervé et al. / Journal of Controlled Release 243 (2016) 146–159IgG1 and IgG2a isotypes (mean antibody titers of 2.9 ± 1.5 log10 versus
b1.5 log10 for the control group, P b 0.05; 2.7 ± 1.4 log10 versus b1.5
log10 for the control group, P b 0.05, respectively) (Fig. 2B). Conversely,
our previous data showed that mice immunized with Viaskin®-Nwith-
out CpG ODN exclusively developed anti-N IgG1 antibody titers after
three applications (data not shown). Then, tomonitormucosal immuni-
ty, anti-N IgG1, IgG2a and IgA antibody responses were evaluated in
broncho-alveolar lavages (BAL) collected at autopsy (Fig. 2C). Anti-N
IgG1 and IgG2a were detectable only in immunized mice (mean anti-
body titers of 1.2 ± 0.8 log10 versus b0.5 log10 for the control group,
P b 0.05 and 1.0 ± 0.9 log10 versus b0.5 log10 for the negative control
group, P= 0.08, respectively). However, no speciﬁc IgA were detected
(mean antibody titers b0.5 log10). Finally, N-speciﬁc cellular response
was evaluated in Viaskin®-N immunizedmice from spleen cells collect-
ed at autopsy and stimulated in vitrowith N-nanorings (Fig. 2D). Spleen
cells collected from the Viaskin®-N immunized mice secreted IFN-ϒ
(P b 0.05 compared to the control group) and, to a lower amount, IL-5
(non-signiﬁcant compared to the control group).
In an attempt to augment themagnitude of these immune responses
and reduce their variability, we increased the number of patch applica-
tion up to 6 of 48 h each (Fig. 3A). We also compared our Viaskin®-N
epicutaneous immunization to intra-nasal and intra-dermal routes.
Mice immunized with Viaskin®-N and CpG-ODN developed higher
levels of anti-N antibodies in sera than in the previous experimentFig. 2. Antibody and cellular responses induced by Viaskin®-N epicutaneous immunization. (A)
N-nanorings and 50 μg of CpG ODN as adjuvant (Viaskin®-N). Viaskin®-N patches were applie
deﬁned as the best application timing for the induction of an optimal speciﬁc immune respons
patches loadedwith excipient alone (PBS) and 50 μg of CpG (Ctrl, in black). (B) N speciﬁc IgG
N-nanorings as a coating, in sera prepared from blood samples collected before (non-im
Viaskin® application (schematized by a red blood drop in panel A). (C) N speciﬁc IgG1
ﬂuids collected at autopsy. (D) Splenocytes were then stimulated in vitro with RPMI med
and IL-5 (right panel) concentrations were measured from cell culture supernatants col
each group (n = 7–8 per experimental group). P values were determined according to thdescribed in Fig. 2 (mean IgG1 titer of 6.1 ± 0.3 log10 versus 1.5 ± 0.1
for the control group at day 35, P b 0.001; mean IgG2a titer of 5.6 ±
0.8 log10 versus 1.6 ± 0.3 for the control group at day 35, P b 0.001)
(Fig. 3B). These titerswere slightly but signiﬁcantly lower than those in-
duced by intra-nasal immunization (mean IgG1 titer of 6.8 ± 0.3 log10;
mean IgG2a titer of 7.1 ± 0.2 log10 at day 35) or intra-dermal immuni-
zation (mean IgG1 titer of 6.6 ± 0.2 log10;mean IgG2a titer of 6.9± 0.2
log10 at day 35). Interestingly, similar levels of IgG1 and IgG2a isotypes
were obtained for all routes of immunization with, however, a slightly
higher IgG1/IgG2a ratio for Viaskin®-N immunized mice (mean ratio
of 12.3 ± 17.8 versus 0.8 ± 1.1 for intra-nasal, P = 0.09 versus 0.2 ±
0.2 for intra-dermal, P = 0.05). In BAL, mice immunized with
Viaskin®-N developed signiﬁcant levels of anti-N Ig(H + L) (mean an-
tibody titer of 3.6 ± 0.3 log10 versus 0.9 ± 0.3 log10 for the control
group, P b 0.001) that was slightly lower than those induced by intra-
nasal or intra-dermal immunizations (mean antibody titers of 4.7 ±
0.2 log10 for intra-nasal and 4.0 ± 0.1 log10 for intra-dermal), whereas
IgA were exclusively induced by intra-nasal immunization (mean anti-
body titers of 2.1 ± 0.1 log10, P b 0.001) (Fig. 3C). Of note, anti-N anti-
body titers were still dispersed upon Viaskin®-N vaccination compared
to intra-nasal or intra-dermal immunizations. However, this dispersion
was largely reduced compared to the results obtained in the previous
set of experiment described in Fig. 2 (standard deviations of 1.6 log10
for IgG1 and 1.4 log10 for IgG2a after 3 patches applications in Fig. 2BALB/c micewere epicutaneously immunizedwith Viaskin® patches loadedwith 50 μg of
d for 48 h on depilated back, three times at twoweeks interval, as indicated. 48 h has been
e in a previous set of experiment (data not shown). As a negative control, mice received 3
1 (upper panel) and IgG2a (lower panel) titers were evaluated by indirect ELISA using
munized: n.i.) or two weeks after the ﬁrst (1st), the second (2nd) or the third (3rd)
, IgG2a and IgA were measured by indirect ELISA using N-rings as a coating, in BAL
ium (negative control, non-stimulated: n.s.) or N-nanorings (N). IFN-ϒ (left-panel)
lected 72 h post-stimulation. Data are mean ± SEM of individual antibody titers for
e Mann-Whitney test (*, P b 0.05; n.s., non-signiﬁcant).
Fig. 3.Antibody responses induced by Viaskin®-N epicutaneous immunization protocol. (A) Sixweeks BALB/cmicewere immunized by epicutaneous application of Viaskin® loadedwith
50 μg of N-nanorings and 25 μg of CpGODN (Viaskin®-N). Viaskin®-Nwas applied for 48 h, 6 times, during 3 consecutiveweeks as indicated. Blood sampleswere collected before the ﬁrst
immunization (day 0: d0) and at days 14 (d14) and 35 (d35) (schematized by red blood drops). As a positive control, mice were immunized with N-nanorings by intra-nasal (in red) or
intra-dermal (in green) routes, twice at twoweeks interval (day 4 and day 18). As a negative control, mice received 6 patches loadedwith excipient alone (PBS) and 50 μg of CpG (Ctrl, in
black). (B) N speciﬁc IgG1 (left panel) and IgG2a (right panel)were evaluated by indirect ELISA usingN-nanorings as coating, in sera prepared fromblood samples collected as described in
panel (A). Data aremean± SEM of individual antibody titers for each group (n= 7–8 per experimental group). (C) N speciﬁc IgG (H+ L) and IgAweremeasured by indirect ELISA using
N-rings as a coating, in BAL ﬂuids collected at autopsy. Data are mean ± SEM of individual antibody titers for each group (n = 7–8 per experimental group). P values were determined
according to the Mann-Whitney test (***, P b 0.001; ****, P b 0.0001). The level of signiﬁcance measured between vaccinated groups was indicated above horizontal capped lines. The
level of signiﬁcance measured between each vaccinated groups and the negative control (Ctrl) group, at day 14 and day 35, was indicated above each histogram bar.
152 P.-L. Hervé et al. / Journal of Controlled Release 243 (2016) 146–159versus 0.3 log10 for IgG1 and 0.8 log10 for IgG2a after 6 patches applica-
tions in Fig. 3).
Having deﬁned an optimized Viaskin®-N immunization protocol in
mice, we then undertook to better qualify, in mice and piglets, the
type of cellular memory responses that have been primed.
3.3. Viaskin®-N epicutaneous immunization induces strong CD4 and CD8
antigen-speciﬁc memory responses in mice and piglets
N-speciﬁc cellular response was evaluated from spleen leukocytes
that were collected at autopsy from immunized mice (Fig. 4) or piglets
(Fig. 5) and further stimulated in vitrowith N-nanorings.
In mice, a similar and signiﬁcant increase of CD4 and CD8 T-cell per-
centageswas noticed for Viaskin®-N, intra-nasal or intra-dermal groups
compared to the control group (Fig. 4A). Importantly, the Viaskin®-N
group was the only vaccinated group showing a signiﬁcant increase of
CD4 and CD8 T-cell antigen-speciﬁc proliferation. In CD4 T-cells, the
percentages of T-Regs, Th1, Th2 and Th17 subpopulations were signiﬁ-
cantly increased for Viaskin®-N and intra-nasal groups (Fig. 4B). For
T-Regs and Th17, this increase was accordingly associated with a signif-
icant secretion of IL-10 and IL-17. Additionally, T-Reg and Th17 antigen-
speciﬁc proliferation was signiﬁcantly higher for the Viaskin®-N group
compared to the control group. The Viaskin®-N group presented a
higher percentage of Th2 cells (P b 0.05 versus intra-nasal and P b 0.01versus intra-dermal) that was accordingly associated with an increase
of Th2 cytokines concentration (P b 0.05 versus intra-nasal; P b 0.001
versus intra-dermal for IL-13; P b 0.01 versus intra-nasal and P b 0.001
versus intra-dermal for IL-5) and the level of IFN-γ was signiﬁcantly
lower (P b 0.01 versus intra-nasal or intra-dermal) (Fig. 4B). Of note,
the level of IFN-γ was higher than the level of Th2 cytokines for both
vaccinated groups (mean IFN-γ/IL-5 ratio of 14 ± 9 for Viaskin®-N,
148 ± 122 for intra-nasal and 882 ± 601 for intra-dermal; mean
IFN-γ/IL-13 ratio of 3.3 ± 2.2 for Viaskin®-N, 23.4 ± 19.6 for intra-
nasal and 90.3 ± 35.6 for intra-dermal), suggesting that the Th1
responsewas generally predominant regardless of the route of immuni-
zation. Interestingly, the levels of IL-2 (involved in the differentiation
and the proliferation of T-cells but also in the maintenance of Tregs
[34]) and GM-CSF (involved in the regulation of T-cell function) were
higher in the Viaskin®-N group (P = 0.05 versus intra-nasal and
P b 0.001 versus intra-dermal for IL-2; P b 0.05 versus intra-nasal and
P b 0.01 versus intra-dermal for GM-CSF) (Fig. 4C).
In piglets, a strong secretion of IFN-γwas observed in leukocyte cul-
ture supernatant at 48 h for the intra-muscularly vaccinated group
(P b 0.001 compared to the negative control group) (Fig. 5B). IFN-γ se-
cretion was also observed for Viaskin®-N vaccinated piglets albeit at a
lower level (P=0.1 compared to the negative control group). However,
Viaskin®-N immunized piglets had an increased proliferation of CD4
and CD8 T-cells as well as of CD4/CD8 negative T-cells (bona ﬁde γδ
Fig. 4. Viaskin®-N epicutaneous immunization induces cellular responses in mice. BALB/c mice were epicutaneously immunized as described in Fig. 3. Splenocytes collected at autopsy
(day 37) were labelled with CFSE and stimulated in vitro with N-nanorings (N) for 96 h at 37 °C + 5% CO2. Then, cells were stained with anti-CD3, anti-CD4 and anti-CD8 antibodies
conjugated to relevant ﬂuorophore (A). Additionally, cells were stained intracellularly with anti-FoxP3, anti-T-bet, anti-GATA-3 and anti-RORγt antibodies conjugated to relevant
ﬂuorophores (B). Cells were analyzed using an LSR Fortessa cytometer. (B, bottom panels and C) Cell culture supernatants were collected after 48 h at 37 °C + 5% CO2 and cytokine
concentration was measured by multiplex analysis. Data are mean + SEM of individual concentration values for each group (n = 6–8 per experimental group). P values were
determined according to the Mann-Whitney test (*, P b 0.05, **, P b 0.01, ***, P b 0.001). The level of signiﬁcance measured between vaccinated groups was indicated above horizontal
capped lines. The level of signiﬁcance measured between each vaccinated groups and the negative control (Ctrl) group was indicated above each histogram bar.
Fig. 5. Immunogenicity of Viaskin®-N epicutaneous vaccine inpiglets. 8weeks pigletswere immunizedwith Viaskin® loadedwithN-nanorings (100 μg) and CpG (100 μg) (Viaskin®-N, in
blue) or CpG alone (100 μg) (Ctrl, in black). Immunization schedule was the same than the one used for mice experiments described in Fig. 3A. As a positive control, piglets were
immunized by intra-muscular injection twice at two weeks interval with 20 μg of N-nanorings, adjuvanted with Montanide™ ISA 71 VG (intra-muscular, in red). Piglets splenocytes,
collected 36 days after the ﬁrst immunization, were labelled with CFSE and stimulated with Xvivo medium (negative control, non-stimulated: n.s.) or N-nanorings (N). (A) Cells were
incubated 48 h at 37 °C and IFN-ϒ was measured from supernatant by sandwich ELISA. Data are expressed as individual fold increase of optical density (O.D.) at 450 nm over O.D. at
450 nm measured from supernatant collected from non-stimulated cells. (B) Cells were incubated for another 48 h at 37 °C + 5% CO2 and then stained with 7-AAD to exclude dead
cells and with anti-CD3, anti-CD4 and anti-CD8 antibodies associated to relevant ﬂuorophore-conjugated secondary antibodies. Cells were analyzed using an LSRFortessa cytometer.
Data are expressed as the individual percentage of proliferation (decrease of CFSE signal) normalized to non-stimulated cells. n = 4–5 per experimental group and P values were
determined according to the Mann-Whitney test (*, P b 0.05; **, P b 0.01).
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T-cells, P= 0.09 for CD8 T-cells and P= 0.03 for γδ T-cells) (Fig. 5C).
This level of proliferation was similar to that measured for splenocytes
obtained from intra-muscular immunized group. Interestingly, no
antibody induction was observed in Viaskin®-N immunized piglets.
To conclude, N-nanorings associated to CpG ODN and administered
repeatedly using Viaskin® patches are highly immunogenic in mice
and piglets and are particularly efﬁcient at inducing both CD8 and CD4
T-cell responses. Interestingly, the T-cell response primed by
Viaskin®-N epicutaneous vaccine in mice was quite different than the
one induced by intra-dermal immunization in terms of magnitude and
orientation, especially concerning T-CD8 and Th17 responses, despite
the vicinity of these two vaccination routes.3.4. Viaskin®-N epicutaneous immunization protects mice against RSV
infection
After challenging vaccinated mice with an RSV-luciferase recombi-
nant virus, viral replication was monitored in lungs at day 4 post-infec-
tion via luminescence detection in living animals. Day 4 corresponds to
the peak of RSV-luciferase replication in mice, as previously described
[30].We comparedViaskin®-N immunization to intra-nasal vaccination
since our previous studies demonstrated that intra-nasal was the most
efﬁcient route for N-nanorings to afford viral protection upon RSV chal-
lenge in mice [11]. Mice vaccinated intranasally or with Viaskin®-N
were completely protected against virus replication in lungs as com-
pared to the control group (P b 0.0001) (Fig. 6A). These resultswere fur-
ther conﬁrmed by the measure of luminescence in lung homogenates
collected during the autopsy performed at day 5 post-infection (Fig.
6B) and by the measure of viral copy number by quantitative RT-PCR,
performed from lung mRNA collected at day 5 post-infection (Fig. S4).Fig. 6. Evaluation of the protective efﬁcacy of Viaskin®-N against RSV infection inmice. BALB/c
37, see Fig. 3A), mice were challengedwith 8.8 × 104 PFU's of recombinant RSV-Luciferase. This
luminescence detection as described in the material andmethods. (A) Viral replication was eva
As an illustration, a snapshot of the back of 6 representative mice of each group is shown on the
infection (n=5per experimental group). As an illustration, a photographof eachwells is shown
valueswere determined according to theMann-Whitney test (****, P b 0.0001; **, P b 0.01). (C) B
as % of initial weight at day 0. Data aremean+ SEM of individual values (n= 10 per experimen
day 5 and day 11 post-infection). The signiﬁcance of the differences observed between the con
infection was evaluated according to the Mann-Whitney test (*, P b 0.05).Controlmice showed a slight reduction in bodyweight fromday 4 to
day 7 post-infection (signiﬁcant at day 7 post-infection as compared to
Viaskin®-N group, P b 0.05) that was not recorded in vaccinated ani-
mals (Fig. 6C). Of note, none of the animals, including in the control
group, developed visible clinical symptoms. Overall, these results indi-
cate that N-nanorings associated to CpG ODN and administered
epicutaneously using Viaskin® patches gave rise to signiﬁcant virologi-
cal and clinical protections against RSV challenge.
3.5. Viaskin®-N epicutaneous vaccine induced limited neutrophil and eo-
sinophil recruitment upon RSV infection, without exacerbating lung
pathology
The analysis of the BAL cell composition, carried out at day 5 post-in-
fection, revealed a similar neutrophil inﬁltration between the Viaskin®-
N group and the control group (mean percentage of 23 ± 4% for the
Viaskin®-N immunized group versus 16 ± 10% for the negative control
group, P=0.4) (Fig. 7A). Of note, the inﬁltration of neutrophils was sig-
niﬁcantly lower for the intra-nasal group (mean percentage of 8 ± 4%,
P b 0.01). At this time-point, the proportion of eosinophils remained
low in all group (mean percentage b1%). At day 11 post infection, a
lower inﬁltration of neutrophils was observed for the two vaccinated
groups compared to the control group (mean percentage of 24 ± 12%
for the control group versus 9 ± 6% for the Viaskin®-N group, P b 0.05
and 8 ± 3% for the intra-nasal group, P b 0.05). At this time-point,
however, the Viaskin®-N group presented a slightly higher inﬁltra-
tion of eosinophils compared to the intra-nasal group and the control
group (mean percentage of 3 ± 3% versus 0.3 ± 0.1% for the intra-
nasal group, P b 0.01 and 0.8 ± 0.5% for the control group, P = 0.1).
Of note, there were no signiﬁcant differences in total cell count be-
tween the three groups at day 11 post-infection, indicating that cell
percentages presented in Fig. 7A were well representative of themice were immunized as described in Fig. 3. Three weeks after the last immunization (day
recombinant virus allowed us to monitor virus replication in the lung of livingmice, using
luated in the lungs of livingmice at day 4 post-infection (n= 10 per experimental group).
right. (B) Viral replication was evaluated from lung homogenates collected at day 5 post-
on the right. Data aremean±SEMof individual values expressed inphotons per second. P
odyweight losswasmonitored daily until day 11 post-infection. Bodyweight is expressed
tal group between day 0 and day 5 post-infection; n= 5 per experimental group between
trol group (Ctrl, black dotted curves) and the Viaskin®-N group (blue line) at day 7 post-
Fig. 7. Lung inﬂammation upon RSV challenge in Viaskin®-N vaccinated mice. BALB/c mice were immunized as described in Fig. 3 and challenged as described in Fig. 6. (A) BAL cells
collected at day 5 or day 11 post-infection from individual mice were stained with May-Grünwald-Giemsa and leukocytes were counted. Percentage of each subset is represented by a
pie chart for each immunized group. (B) The concentration of KC (GRO-α/CXCL-1) was determined from lung homogenates and the concentration TNF-alpha and Eotaxin were
determined from BAL collected at day 5 post-infection by multiplex analysis. (C) The concentration of CCL-2, CCL-7, CCL-4 and CXCL-10 was determined from lung homogenates
collected at day 5 post-infection by multiplex analysis. Data are mean + SEM of individual values (n = 5 per experimental group). P values were determined according to the Mann-
Whitney test (*, P b 0.05; **, P b 0.01).
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observation, the concentration of pulmonary KC, TNF-α and eotaxin ob-
served for the Viaskin®-N group were similar to those observed for the
control group, but signiﬁcantly higher to those measured in the intra-
nasal group (P b 0.05 for KC concentration and P b 0.01 for TNF-α and
eotaxin concentrations) (Fig. 7C). Furthermore, the level of inﬂammatory
cytokines IL-1 Beta and IL-6 observed for the Viaskin®-N group was sig-
niﬁcantly higher to that measured for the intra-nasal group (P b 0.05 for
IL-1 Beta concentration and P b 0.01 for IL-6 concentration). Additionally,
the levels of monocyte-recruiting cytokines CCL-2 and CCL-7 and the
levels of DC-recruiting cytokines CCL-4 and CXCL-10 were signiﬁcantly
higher to those observed for the intra-nasal group (P b 0.01 for CCL-2,
P b 0.05 for CCL-7, P b 0.01 for CCL-4 and P b 0.01 for CXCL-10)
(Fig. 7C). At ﬁrst instance, these results could be interpreted as a slight
exacerbation of lung inﬂammation and pathology after Viaskin®-N im-
munization. However, histological staining of the lung sections per-
formed at day 11 post-infection did not revealed any signs of lung
pathology or scar tissue, despite a slightly higher secretion of mucus
in bronchioles for both vaccinated groups as compared to control
group (Fig. 8). Moreover, the level of inﬂammatory cytokines induced
after Viaskin®-N immunization was similar or even lower to that in-
duced in the control group (Fig. 7). Overall, these data indicate thatViaskin®-N epicutaneous vaccine induces a limited lung inﬂammation
upon RSV challenge that is not associated with lung injury.
3.6. RSV infection revealed the priming of Th1, Th17 and Treg responses
upon Viaskin®-N epicutaneous vaccination
The levels of pulmonary Th1 (IFN-γ) and Th2 (IL-4, IL-13) cytokines
observed for Viaskin®-N vaccinated mice at day 5 post-infection were
similar to those observed for the control group (P = 0.3 for IFN-γ,
P = 0.7 for IL-4 and P = 0.8 for IL-13) but signiﬁcantly higher than
those observed for the intra-nasal group (P b 0.01). On the other hand,
the level of the Th1-associated cytokine IL12p70 was signiﬁcantly
higher in the Viaskin®-N group than in the control group (P b 0.05)
and the intra-nasal group (P b 0.01). (Fig. 9, left panels). Of note, the
level of these cytokines was also measured from lung samples collected
at day 11 post-infection, but concentrations were low or undetectable
for all groups. Additionally, the pulmonary concentrations of IL-17A
and IL-23 were higher for the Viaskin®-N group (P b 0.05 versus the
control group and P b 0.01 versus the intra-nasal group for IL-17 concen-
tration) (Fig. 9). These results are consistent with the data obtained in
spleen (Fig. 4), and is an indication of a Th17 immune orientation
after Viaskin®-N epicutaneous immunization. This Th17 orientation
Fig. 8. Histological analysis of lung upon RSV challenge in Viaskin®-N vaccinated mice. BALB/c mice were immunized as described in Fig. 3 and challenged as described in Fig. 6. Lungs
collected at day 11 post-infection were ﬁxed in PBS-PFA, embedded in parafﬁn and sliced. Lung sections were colored using Hematoxylin Eosin Safran (HES) or alcian blue and images
were acquired using slide scanner. The presence of mucus is indicated by black arrows.
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crease in neutrophils recruitment observed in the Viaskin®-N group
upon infection (Fig. 7A and B). A slight increase of IL-10 concentration
was also observed in BAL for the Viaskin®-N group, suggesting that
Viaskin®-N also induce an immuno-modulatory response in lung (Fig.
9, right panel). To conﬁrm these results, the expression of IL-17 and
FoxP3was evaluated byquantitative RT-PCR for Viaskin®-N immunized
mice and the control group using mRNA extracted from lungs collected
at day 5 post infection. A signiﬁcant increase of IL-17 and FoxP3mRNA
expression was measured compared to the control group (Fig. S5),
conﬁrming that Viaskin®-N also stimulated a Treg response in lung
that might limit a potential RSV-induced immuno-pathology.Fig. 9. Viaskin®-N immunization promoted a local Th1/Th17 oriented immune response upo
described in Fig. 6. The level of IFN-γ, IL-5, IL-13, IL-12p70, IL-17 and IL-23 cytokines was det
was determined from BAL collected at day 5 post-infection, by multiplex analysis. Data a
determined according to the Mann-Whitney test (*, P b 0.05; **, P b 0.01).4. Discussion
The objective of the present studywas the preclinical evaluation of a
prophylactic epicutaneous vaccine against RSV that combines two inno-
vative technologies: Viaskin® patches as an epicutaneous delivery plat-
form on intact skin and RSV nucleoprotein nanorings (N-nanorings) as
an antigen. In 2003, Godefroy et al. ﬁrst demonstrated the feasibility of
an epicutaneous vaccine against RSV in mice. In that study, authors
used recombinant polypeptides containing a G protective epitope
(G2Na), adjuvanted with cholera toxin (CT), applied by wetting on
shaved skin [35]. However, although G2Nawas able to give a signiﬁcant
level of protection against RSV challenge, speciﬁc antibody titers weren RSV challenge. BALB/c mice were immunized as described in Fig. 3 and challenged as
ermined from lung homogenates collected at day 5 post-infection and the level of IL-10
re mean + SEM of individual values (n = 5 per experimental group). P values were
157P.-L. Hervé et al. / Journal of Controlled Release 243 (2016) 146–159low, highly heterogeneous and mostly of IgG1 isotype, indicating a Th2
orientation that may be associated to immuno-pathology and disease
enhancement upon RSV challenge. Unfortunately, the effective pres-
ence of a vaccine-induced disease enhancement was not evaluated in
that study.
In the present work, we demonstrated that Viaskin® patches loaded
with N-nanorings and CpG ODN as adjuvant (Viaskin®-N) were immu-
nogenic in mice and piglets, by potently priming N-speciﬁc memory
CD4 and CD8 T-cells, as well as CD4/CD8 negative T-cells in piglets,
bona ﬁde γδ T-cells. As we mentioned in the introduction, the presence
of this N-speciﬁc cellular response is a good indicator of vaccine efﬁcacy
since it has been correlated with viral protection in previous studies
[11]. Moreover, CD8 T-cells are known to participate to viral clearance
upon RSV infection in mice and human [36,37]. The effective role of γδ
T-cells in the context of RSV infection is, however, poorly understood
but they might participate in the reduction of RSV-associated immuno-
pathology [38]. On, the other hand, anti-N humoral response, although
it possesses no proven role in protection, was used here as an efﬁcient
marker for immunogenicity in mice. In piglets, however, it was not pos-
sible to observe any induction of antibody responses against N (data not
shown). Interestingly, these results could be related to clinical data ob-
tained by Combadière et al., showing a signiﬁcant and selective increase
of speciﬁc CD8 T-cells after transcutaneous immunization with
inactivated inﬂuenza virus, without induction of neutralizing antibodies
[39]. In agreement with our data, these results suggests an intrinsic de-
fect of Langerhans cells (LC)-mediated immune response to induced a
humoral response, as previously observed in vitro for human LC [40].
However, some patches formulations (adjuvant) or therapeutic
schemes (number of application)might be able to overcome this limita-
tion as observed in mice study [41]. In mice, indeed, our Viaskin®-N
epicutaneous vaccine induced a well-balanced IgG1/IgG2a speciﬁc anti-
body response and primed Th1 CD4 T-cells. Of note, this Th1 orientation
observed after epicutaneous vaccinationwas lessmarked than for intra-
nasal and intra-dermal immunizations. The use of CpG ODN as an adju-
vant probably contributed to this Th1 orientation. Indeed, CpG ODN
possesses an intrinsic capacity to drive the immune response toward
the Th1 phenotype, via triggering TLR9 pathway in antigen-presenting
cells (APC) [42]. We chose CpG ODN as an adjuvant based on our previ-
ously published data, showing that the addition of CpGODN to N-nano-
rings administered intranasally in neonate mice helped to prevent the
Th2 bias of the recall response and reduced the eosinophilic reaction ob-
served upon RSV challenge [33]. This choice was further supported by
other studies demonstrating that CpGODNused as an adjuvant in trans-
cutaneous vaccine approaches was able to increase vaccine immunoge-
nicity and the differentiation of speciﬁc Th1 cells [43–45]. Importantly,
CpG ODN has been demonstrated as a safe and well tolerated adjuvant
in a phase 1 clinical trial of an HBV vaccine in HIV-seropositive adults
[46].
Remarkably, Viaskin®-N epicutaneous vaccine also primed CD4
T-lymphocytes from the RORγt+ (Th17) and the FoxP3+ regulatory
cell (Tregs) subsets in mice. These Th17 and Tregs were identiﬁed
in splenocytes upon antigen-speciﬁc stimulation and locally in the
lung upon RSV infection. The role of the Th17 response in the phys-
iopathology of RSV infection still remains controversial. Indeed,
Th17 response seems to possess a bit of duplicity in the context of
RSV infection. On the one hand, numerous studies suggest that the
Th17 response would be beneﬁcial in some cases of RSV infection
[47]. For example, local IL-17 production might accelerate recovery
of RSV infection in non-ventilated patients [48]. On the other hand,
an exacerbated Th17 responsemight be responsible for acute inﬂam-
mation and pathology notably by promoting the production of
chemokines such as KC, CCL20 (MIP-3α) and IL-6 by stromal cells
which then promote neutrophil recruitment to the lung [47]. The
stimulation of a Th17 response by Viaskin®-N could indeed explain
our ﬁndings showing a slight increase of neutrophils recruitment
and a signiﬁcant increase of TNF-α secretion in the lung upon RSVchallenge. However, in our case, this Th17 response was not associat-
ed with disease exacerbation upon challenge. Indeed, Viaskin®-N
vaccinated mice presented an inﬂammatory cytokine production
pattern in the lung that was similar to that observed for the control
group upon RSV challenge. Additionally, Viaskin®-N vaccinated
mice were totally protected from RSV replication in the lung, which
is the main site of infection, without any weight loss, clinical symp-
toms or signs of lung injury. Of note, we used an immunogen dose
and an immunization schedule that was optimal to afford viral pro-
tection in the lung. Indeed, a signiﬁcant increase of pulmonary viral
load was observed when the number of Viaskin®-N application
was decrease twofold (i.e. one patch per week instead of two) (Fig.
S4). However, viral protection was still signiﬁcant compared to the
control group (P b 0.05).
Indeed, the degree of pulmonary disease caused by RSV infection is
highly dependent on a ﬁne regulation between pro-inﬂammatory and
regulatory immune responses [49]. Tregs has especially been shown
to efﬁciently hang in this balance by inhibiting Th2 associated immune
responses and by limiting eosinophils inﬁltration in the lung upon RSV
infection that are the primary cause of RSV-induced lung immunopa-
thology [50,51]. More speciﬁcally, the importance of Treg/Th17 balance
in the pathogenesis of RSV infection has been highlighted [49]. Indeed,
it has been shown that the percentage of Tregs and the levels of IL-10
and TGF-βwere signiﬁcantly lower in infants suffering from RSV bron-
chiolitis than in non-RSV pneumonia-suffering or healthy infants [52].
Conversely, the percentage of Th17 and the level of IL-17 was found
higher in these RSV bronchiolitis-suffering individuals. Moreover, Treg
and Th17 populations seems closely interconnected since differentia-
tion of Tregs into Th17 have been recorded in a previous experiment
[53]. In our case, the stimulation of Treg by Viaskin®-N vaccination
might therefore prevents from a deleterious Th17 immune response
and explain the absence of detectable macroscopic andmicroscopic pa-
thology upon challenge. In fact, the capacity of Viaskin®-N to stimulate
Treg response could be linked to the Viaskin® platform itself that has
been initially designed to induce tolerance to allergens. Indeed, our pre-
vious studies demonstrated that allergens applied on intact skin with
Viaskin® patches efﬁciently promote a down-modulation of speciﬁc
immune response in sensitized mice in association with the induction
of Tregs [16,20,21]. This unique particularity could be related to the
unique targeting of LC [21], mainly described to promote regulatory
T cell responses [54,55]. This tolerogenic immune-modulation could
be obtained only when the antigen is administered on intact skin
[19]. In human, LC have also been shown to maintained the Treg
pool [55] but also, in agreement with our data, to preferentially induce
Th17 responses [56]. Originally, Viaskin®-N epicutaneous vaccine
would advantageously combine the induction a protective immunity
against RSV replication to the avoidance of the Th2-mediated vaccine
enhance disease that could occurs upon RSV challenge [3], by the induc-
tion of immuno-modulatory T-cell.
In piglets, we demonstrated that Viaskin® patches were able to pro-
mote the passage of N-nanorings fused to GFP (N-GFP) to the epidermis,
resulting in an efﬁcient capture of N-GFP by LC. Bearing inmind the sim-
ilarity between swine and human skin, a similar uptake of N-nanorings
by LC could be expected in human. Therefore, these results are really en-
couraging, especially with regards to the feasibility of Viaskin® vaccina-
tion in human.
Our recent data demonstrated that N-nanorings can be used as a po-
tent vaccine carrier for heterologous antigens such as inﬂuenza M2
ectodomain (M2e) [29]. In light of these results, we undertook to fuse
a neutralizing epitope derived from RSV F protein to N. Such chimeric
N-nanorings (N-Fe) would present the advantage to combine a potent
cellular response (afforded by N) to a neutralizing antibody response
(afforded by the F epitope). These N-Fe are still under optimization for
their use in combinationwithViaskin®patches. For now, the evaluation
of their antigenicity and their protective potency inmice using “conven-
tional” immunization routes has given interesting results [57].
158 P.-L. Hervé et al. / Journal of Controlled Release 243 (2016) 146–159Very recently, Gavillet et al. demonstrated that a single application of
Viaskin® patches loaded with detoxiﬁed pertussis toxin and/or
pertactin and ﬁlamentous hemagglutinin, without adjuvant, was efﬁ-
cient to reactivate vaccine-induced pertussis immunity in mice and to
protect mice against a B. pertussis challenge [23]. Furthermore, this
booster vaccine candidate will soon be tested in a phase I clinical trial.
These promising results raised a great deal of hope concerning the use
of Viaskin® patches as a non-invasive vaccine delivery method. Com-
bined to our present results, these data also highlighted the potential
versatility of the Viaskin® platform.
Besides immunological aspects Viaskin®-N epicutaneous vaccine
would presents several advantages compared to other vaccine candi-
dates. First, the immunization protocol is needle free and, unlike other
transcutaneous vaccines, does not require skin preparation before ap-
plication. Therefore, this painless vaccine may have a better acceptabil-
ity for the vaccination of sensible population such as young children.
Secondly, this easy-to-use and potentially self-applicative vaccination
method is expected to overcome some issues associated with injectable
vaccinations such as the need of sterile medical devices and skilled
health-care professionals or the requirement of stringent store condi-
tions and the maintenance of cold-chain. Paradoxically, these issues
are especially marked in developing countries where RSV infections
constitute the most serious burden [58].
5. Conclusion
In the present study, we demonstrated the feasibility of an
epicutaneous RSV vaccine using Viaskin® patches. The unique proper-
ties of Viaskin® epicutaneous patches permitted to efﬁciently protect
mice against RSV replication, while actively avoiding RSV-associated
lung immuno-pathology by the stimulation of Treg response. Impor-
tantly, the signiﬁcant level of protection obtained in the lung suggest
that Viaskin®-N vaccine would prevent bronchiolitis and pneumonia,
the most severe clinical manifestations of RSV infection triggered by
the virus replication in the deep respiratory tract. In addition, Viaskin®
patches as a non-invasive vaccine platform might be particularly suit-
able for the vaccination of young children. Overall, Viaskin® patches
combined to N-nanorings would constitute a pertinent and promising
vaccine strategy against RSV. From these results and those obtained
with B. pertussis [23], it becomes apparent that the Viaskin® patch con-
stitutes an effective vaccine device for the development of innovative
and non-invasive prophylactic treatments against pathogens.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2016.10.003.
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